Akbar S M, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, Michitaka K, Horiike N, Onji M
Third Department of Internal Medicine, Ehime University School of Medicine, Shigenobu-Cho, Ehime, Japan.
Cancer Lett. 2001 Oct 10;171(2):125-32. doi: 10.1016/s0304-3835(01)00606-1.
The levels of macrophage migration inhibitory factor (MIF), a proinflammatory and carcinogenic cytokine, were significantly higher in the sera from patients with hepatocellular carcinoma (HCC; 25.6+/-15.3 ng/ml, n=55) and liver cirrhosis (LC; 18.9+/-10.7 ng/ml, n=26) compared with sera from patients with gastrointestinal cancer (6.8+/-7.5 ng/ml, n=29) and normal controls (5.6+/-1.2 ng/ml, n=45; P<0.01). Hepatocytes from patients with LC and HCC, but not from chronic hepatitis, expressed very high levels of MIF. A possible association between overexpression of MIF and hepatocarcinogenesis is suggested.
促炎致癌细胞因子巨噬细胞移动抑制因子（MIF）在肝细胞癌（HCC；25.6±15.3 ng/ml，n = 55）和肝硬化（LC；18.9±10.7 ng/ml，n = 26）患者血清中的水平显著高于胃肠道癌患者（6.8±7.5 ng/ml，n = 29）和正常对照者（5.6±1.2 ng/ml，n = 45；P<0.01）。LC和HCC患者的肝细胞而非慢性肝炎患者的肝细胞表达非常高水平的MIF。提示MIF过表达与肝癌发生之间可能存在关联。
